Jung et al. BMC Cancer 2012, 12:382 http://www.biomedcentral.com/1471-2407/12/382 17. Natrajan R, Weigelt B, Mackay A, Geyer FC, Grigoriadis A, Tan DS, Jones C, Lord CJ, Vatcheva R, Rodriguez-Pinilla SM, Palacios J, Ashworth A, Reis-Filho JS: An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat 2010, 121:575–589. 18. Russnes HG, Vollan HK, Lingjaerde OC, Krasnitz A, Lundin P, Naume B, Sørlie T, Borgen E, Rye IH, Langerød A, Chin SF, Teschendorff AE, Stephens PJ, Månér S, Schlichting E, Baumbusch LO, Kåresen R, Stratton MP, Wigler M, Caldas C, Zetterberg A, Hicks J, Børresen-Dale AL: Genomic architecture characterizes tumor progression paths and fate in breast cancer patients. Sci Transl Med 2010, 2:38–47. 19. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature 2000, 406:747–752. 20. Jung SH, Shin SH, Yim SH, Choi HS, Lee SH, Chung YJ: Integrated analysis of copy number alteration and RNA expression profiles of cancer using a high-resolution whole-genome oligonucleotide array. Exp Mol Med 2009, 41:462–470. 21. Kim SY, Nam SW, Lee SH, Park WS, Yoo NJ, Lee JY, Chung YJ: ArrayCyGHt: a web application for analysis and visualization of array-CGH data. Bioinformatics 2005, 21:2554–2555. 22. Yim SH, Chung YJ, Jin EH, Shim SC, Kim JY, Kim YS, Hu HJ, Shin SH, Pae HO, Zouali M, Chung HT: The potential role of VPREB1 gene copy number variation in susceptibility to rheumatoid arthritis. Mol Immunol 2011, 48:1338–1343. 23. Agrawal R, Imielinski T, Swami A: Database mining: A performance perspective. IEEE T KNOWL DATA EN 1993, 5:914–925. 24. Yin X, Han J: CPAR: Classification based on predictive association rules. In: SIAM International Conference of Data Mining. San Fransisco, CA: SIAM; 2003:331–335. 25. van Beers EH, Nederlof PM: Array-CGH and breast cancer. Breast Cancer Res 2006, 8:210. 26. Lightfoot HM Jr, Lark A, Livasy CA, Moore DT, Cowan D, Dressler L, Craven RJ, Cance WG: Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis. Breast Cancer Res Treat 2004, 88:109–116. 27. Hwang KT, Han W, Cho J, Lee JW, Ko E, Kim EK, Jung SY, Jeong EM, Bae JY, Kang JJ, Yang SJ, Kim SW, Noh DY: Genomic copy number alterations as predictive markers of systemic recurrence in breast cancer. Int J Cancer 2008, 123:1807–1815. 28. Cano CE, Hamidi T, Sandi MJ, Iovanna JL: Nupr1: The swiss-knife of cancer. J Cell Physiol 2011, 226:1439–1443. 29. Ree AH, Tvermyr M, Engebraaten O, Rooman M, Røsok O, Hovig E, Meza-Zepeda LA, Bruland OS, Fodstad O: Expression of a novel factor in human breast cancer cells with metastatic potential. Cancer Res 1999, 59:4675–4680. 30. Chowdhury UR, Samant RS, Fodstad O, Shevde LA: Emerging role of nuclear protein 1 (NUPR1) in cancer biology. Cancer Metastasis Rev 2009, 28:225–232. 31. Khoury T, Kanehira K, Wang D, Ademuyiwa F, Mojica W, Cheney R, Morrison C, Conroy J, Nowak N, Liu S: Breast carcinoma with amplified HER2: a gene expression signature specific for trastuzumab resistance and poor prognosis. Mod Pathol 2010, 23:1364–1378. 32. Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, Pylkkänen L, Turpeenniemi-Hujanen T, von Smitten K, Lundin J: Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 2003, 9:923–930. 33. Joerger M, Thürlimann B, Huober J: Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment? Ann Oncol 2011, 22:17–23. 34. Macrinici V, Romond E: Clinical updates on EGFR/HER targeted agents in early-stage breast cancer. Clin Breast Cancer 2010, 10(Suppl 1):E38–46. 35. Yim SH, Kim TM, Hu HJ, Kim JH, Kim BJ, Lee JY, Han BG, Shin SH, Jung SH, Chung YJ: Copy number variations in East-Asian population and their evolutionary and functional implications. Hum Mol Genet 2010, 19:1001–1008. 36. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, Kingsley C, Page 11 of 11 Dairkee S, Meng Z, Chew K, Pinkel D, Jain A, Ljung BM, Esserman L, Albertson DG, Waldman FM, Gray JW: Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006, 10:529–541. 37. Kallioniemi OP, Kallioniemi A, Kurisu W, Thor A, Chen LC, Smith HS, Waldman FM, Pinkel D, Gray JW: ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA 1992, 89:5321–5325. 38. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177–182. 39. Kim YS, Won YS, Park KS, Song BJ, Kim JS, Oh SJ, Jeon HM, Jung SS, Park WC: Prognostic significance of HER2 gene amplification according to stage of breast cancer. J Korean Med Sci 2008, 23:414–420. doi:10.1186/1471-2407-12-382 Cite this article as: Jung et al.: Simultaneous copy number gains of NUPR1 and ERBB2 predicting poor prognosis in early-stage breast cancer. BMC Cancer 2012 12:382. Submit your next manuscript to BioMed Central and take full advantage of: • Convenient online submission • Thorough peer review • No space constraints or color ﬁgure charges • Immediate publication on acceptance • Inclusion in PubMed, CAS, Scopus and Google Scholar • Research which is freely available for redistribution Submit your manuscript at www.biomedcentral.com/submit